ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Sees Significant Drop in Short Interest

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) saw a significant decrease in short interest in April. As of April 15th, there was short interest totalling 460,800 shares, a decrease of 20.6% from the March 31st total of 580,600 shares. Based on an average daily trading volume, of 2,410,000 shares, the short-interest ratio is presently 0.2 days. Approximately 6.1% of the shares of the stock are sold short.

ZyVersa Therapeutics Stock Performance

NASDAQ:ZVSA opened at $5.77 on Tuesday. The stock’s 50-day moving average is $7.64 and its 200-day moving average is $14.20. ZyVersa Therapeutics has a 1-year low of $4.44 and a 1-year high of $220.85.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and set a $120.00 price objective on shares of ZyVersa Therapeutics in a report on Tuesday, March 26th.

About ZyVersa Therapeutics

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.